Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

石四藥集團有限公司
SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT
UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the "Board") of SSY Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group's Bevantolol Hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market, being the third of such approvals for the PRC entities.

Bevantolol Hydrochloride is mainly used for the treatment of primary hypertension, and is a new generation of highly selective α1 and β1 dual receptor blocker. It blocks cardiac β1 receptors, which steadily slows down heart rate and reduces myocardial contractility. On the other hand, it blocks vascular α1 receptors, which directly dilate peripheral blood vessels and reduce vascular resistance. At the same time, it inhibits renin release. With such multi-target synergistic blood pressure stabilization, it can achieve stable blood pressure control for 24 hours and hence is a new type of antihypertensive drug with comprehensive upgraded mechanism.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 13 November 2026

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Meng Guo, Mr. Chow Hing Yeung, Ms. Qu Wanrong and Mr. Wu Hengyao as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.